Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes
AK Marwaha, S Tan, JP Dutz - Clinical immunology, 2014 - Elsevier
Abstract Type 1 diabetes (T1D) results from the autoimmune destruction of insulin-producing
pancreatic beta cells. There is now mounting evidence that pro-inflammatory pathways,
which are mediated by T cells that secrete IL-17 and IFN-γ, play a critical role in the loss of
beta cells. These data suggest that blockade of T cells that secrete IL-17 and IFN-γ may halt
or reverse disease in subjects with recent-onset T1D. Agents to facilitate this approach are
currently in clinical use. Ustekinumab, a humanized monoclonal antibody that targets the …
pancreatic beta cells. There is now mounting evidence that pro-inflammatory pathways,
which are mediated by T cells that secrete IL-17 and IFN-γ, play a critical role in the loss of
beta cells. These data suggest that blockade of T cells that secrete IL-17 and IFN-γ may halt
or reverse disease in subjects with recent-onset T1D. Agents to facilitate this approach are
currently in clinical use. Ustekinumab, a humanized monoclonal antibody that targets the …